Related Experiment Video
Updated: Jul 17, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Novel targeted therapies for non-small cell lung cancer
Philip W Smith1, Chadrick E Denlinger, David R Jones
1University of Virginia, School of Medicine, P.O. Box 800679, Lee Street, Charlottesville, VA 22908-0679, USA.
Abstract:
Targeted therapies will advance the treatment of NSCLC as we improve our understanding of the underlying biology of NSCLC and enhance our ability to clinically target the optimal therapy to an individual's cancer. Ongoing translational research including tissue arrays, genomic, and proteomic studies will help to identify clinically useful biomarkers that will allow further classification of NSCLC and may allow accurate prediction of response to specific chemotherapeutic regimens. Advances in targeted therapy in NSCLC are already yielding exciting results, and promises to become an increasingly important adjunct to surgical management of NSCLC.
Insights
Targeted therapies offer promising advancements in non-small cell lung cancer (NSCLC) treatment. Further research into NSCLC biology and biomarkers will enable personalized treatment strategies for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Translational Research
Background:
- Non-small cell lung cancer (NSCLC) treatment is evolving.
- Understanding NSCLC biology is crucial for therapeutic advancements.
Purpose of the Study:
- To explore the role of targeted therapies in NSCLC treatment.
- To highlight the importance of translational research in identifying biomarkers for personalized medicine.
Main Methods:
- Genomic and proteomic studies.
- Translational research utilizing tissue arrays.
Main Results:
- Identification of potential biomarkers for NSCLC classification.
- Potential for predicting patient response to specific chemotherapeutic regimens.
Conclusions:
- Targeted therapies are advancing NSCLC treatment.
- Biomarker discovery through translational research is key to personalized NSCLC care.
- Targeted therapy will be an important adjunct to NSCLC surgery.
More Related Videos
07:59Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy